BBIO Share Price Performance
US$67.91
31.66 (87.34%)
20.7% undervalued intrinsic discount
US$85.68
Fair Value
Price US$67.91
unknown US$85.68
AnalystConsensusTarget US$89.79
AnalystHighTarget US$127.69
Fair ValueUS$85.68
Share Pricen/a
BridgeBio Pharma, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 35 Fair Values set on narratives written by author
BBIO Community Narratives
UN
Fair Value US$85.68 20.7% undervalued intrinsic discount
BridgeBio Pharma (BBIO) From Biotech Blueprint to Commercial Powerhouse
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$89.79 24.4% undervalued intrinsic discount
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$127.69 46.8% undervalued intrinsic discount
Advances In Genomics And AI Will Expand Rare Disease Markets
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
BridgeBio Pharma (BBIO) From Biotech Blueprint to Commercial Powerhouse
BridgeBio Pharma (BBIO) has successfully transitioned into a commercial-stage juggernaut, with shares trading at $68.14 as of February 22, 2026. The company is currently riding the momentum of its primary growth engine, Attruby (acoramidis) , which reported preliminary 2025 revenues of $362.4 million.Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rising Global Price Controls And Costs Will Curb Future Prospects
Key Takeaways Heavy reliance on a single lead asset and limited pipeline heightens exposure to regulatory, commercial, and market access risks that could severely impact growth and profitability. High operating expenses and rising competition challenge sustained profitability, while regulatory pressures threaten pricing power and delay future product launches.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$80
15.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
76.68% p.a.
Profit Margin
7.1%
Future PE
143.12x
Price in 2029
US$98.46
Advances In Genomics And AI Will Expand Rare Disease Markets
Key Takeaways BridgeBio's innovative therapies, market access strategy, and late-stage pipeline position it for outsized revenue growth and durable margin expansion beyond analyst expectations. Advances in drug discovery, robust financial partnerships, and a growing patient base support sustained product launches and accelerating earnings growth.Read more
31
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$127.69
46.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
104.18% p.a.
Profit Margin
38.43%
Future PE
27.28x
Price in 2029
US$156.71
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
Key Takeaways Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins. Efficient commercialization strategy and ample cash reserves support future product launches without requiring immediate equity dilution, strengthening operational leverage.Read more
249
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$89.79
24.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
82.84% p.a.
Profit Margin
26.93%
Future PE
38.07x
Price in 2029
US$110.06
Trending Discussion
Recently Updated Narratives
UN
BridgeBio Pharma (BBIO) From Biotech Blueprint to Commercial Powerhouse
Fair Value: US$85.68 20.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase
Fair Value: US$80 15.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing
Fair Value: US$127.69 46.8% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BridgeBio Pharma, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 24, 2026
- -4.14
- 95.78%
- -225.31%
- -96.3%
About BBIO
- Founded
- 2015
- Employees
- 728
- CEO
- WebsiteView website
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
